Covered recipient · General Payments record
GREGORY T GREENWOOD
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$74,239.71
144 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,930.00 | 47 |
| Travel and Lodging | $3,362.95 | 28 |
| Food and Beverage | $2,965.95 | 66 |
| Consulting Fee | $862.00 | 1 |
| Education | $118.81 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $52,517.55 | 84 |
| Otsuka America Pharmaceutical, Inc. | $10,269.34 | 11 |
| Alexion Pharmaceuticals, Inc. | $9,713.37 | 19 |
| Baxter Healthcare | $862.00 | 1 |
| Vifor Pharma, Inc. | $296.80 | 5 |
| GlaxoSmithKline, LLC. | $143.36 | 6 |
| Amgen Inc. | $103.18 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $93.90 | 4 |
| Mallinckrodt Hospital Products Inc. | $86.43 | 3 |
| Horizon Therapeutics plc | $56.60 | 3 |
| Aurinia Pharma U.S., Inc. | $49.28 | 2 |
| OPKO Pharmaceuticals, LLC | $31.53 | 2 |
| Bard Peripheral Vascular, Inc. | $16.37 | 1 |
Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GREGORY T GREENWOOD
NPI 1316946858 · CMS profile ID 241465
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
WINSTON-SALEM, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GREGORY T GREENWOOD, NPI 1316946858, CMS profile ID 241465. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). GREGORY T GREENWOOD, NPI 1316946858, CMS profile ID 241465. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- GREGORY T GREENWOOD, NPI 1316946858, CMS profile ID 241465, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
144 matching records · $74,239.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 144.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 10/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829468765 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,000.00 | 10/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829804177 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.00 | 10/07/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829547987 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.40 | 10/07/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829636807 | CMS |
| AstraZeneca Pharmaceuticals LP | $192.50 | 10/07/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829796021 | CMS |
| AstraZeneca Pharmaceuticals LP | $107.60 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829984883 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,350.00 | 10/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829988671 | CMS |
| AstraZeneca Pharmaceuticals LP | $122.08 | 10/07/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829998721 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $23.16 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789088215 | CMS |
| AstraZeneca Pharmaceuticals LP | $101.45 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829592923 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,000.00 | 10/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829398015 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.67 | 09/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829374593 | CMS |
| AstraZeneca Pharmaceuticals LP | $45.14 | 09/29/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829901333 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829994677 | CMS |
| Alexion Pharmaceuticals, Inc. | $15.91 | 09/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783141089 | CMS |
| AstraZeneca Pharmaceuticals LP | $650.00 | 09/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829638429 | CMS |
| Vifor Pharma, Inc. | $23.52 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816129863 | CMS |
| GlaxoSmithKline, LLC. | $13.86 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801725391 | CMS |
| Amgen Inc. | $22.57 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826343601 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 09/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830093855 | CMS |
| Horizon Therapeutics plc | $17.67 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797137467 | CMS |
| AstraZeneca Pharmaceuticals LP | $120.37 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829604003 | CMS |
| AstraZeneca Pharmaceuticals LP | $117.60 | 08/31/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829785955 | CMS |
| GlaxoSmithKline, LLC. | $73.35 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802137089 | CMS |
| Bard Peripheral Vascular, Inc. | $16.37 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837151875 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.80 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830005859 | CMS |
| AstraZeneca Pharmaceuticals LP | $650.00 | 08/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829678165 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.36 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829703379 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,350.00 | 08/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829416455 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,350.00 | 08/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830120639 | CMS |
| Horizon Therapeutics plc | $19.76 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797137463 | CMS |
| AstraZeneca Pharmaceuticals LP | $650.00 | 08/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830193947 | CMS |
| AstraZeneca Pharmaceuticals LP | $650.00 | 08/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829271031 | CMS |
| AstraZeneca Pharmaceuticals LP | $132.14 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829809213 | CMS |
| AstraZeneca Pharmaceuticals LP | $66.08 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829878575 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.45 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830069613 | CMS |
| AstraZeneca Pharmaceuticals LP | $126.56 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830104777 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $24.94 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789098707 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,000.00 | 08/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829894381 | CMS |
| AstraZeneca Pharmaceuticals LP | $115.95 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829552171 | CMS |
| AstraZeneca Pharmaceuticals LP | $650.00 | 07/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829561839 | CMS |
| AstraZeneca Pharmaceuticals LP | $79.52 | 07/29/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829850809 | CMS |
| Otsuka America Pharmaceutical, Inc. | $15.78 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834733023 | CMS |
| Alexion Pharmaceuticals, Inc. | $960.00 | 07/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783141105 | CMS |
| GlaxoSmithKline, LLC. | $20.37 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802995595 | CMS |
| Otsuka America Pharmaceutical, Inc. | $1,620.00 | 07/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834733021 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 07/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829962023 | CMS |
| Mallinckrodt Hospital Products Inc. | $32.58 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845358149 | CMS |
| Vifor Pharma, Inc. | $24.40 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 816118319 | CMS |
| AstraZeneca Pharmaceuticals LP | $110.70 | 07/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829799917 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $548.12 | 6 |
| PY2025 | Principal investigator | $1,129,847.75 | 30 |
| PY2024 | Recipient | $2,000.00 | 1 |
| PY2024 | Principal investigator | $392,464.35 | 18 |
| PY2023 | Principal investigator | $184,406.29 | 161 |
| PY2022 | Principal investigator | $209,906.66 | 77 |
| PY2021 | Principal investigator | $411,211.84 | 135 |
| PY2020 | Principal investigator | $456,136.17 | 166 |
| PY2019 | Principal investigator | $320,420.78 | 242 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $61,844.82 | 12/18/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH | a phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis through a central venous catheter | No dispute reported | 06/30/2026 | 1185551629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27,160.00 | 12/17/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699468 |
| Principal investigator 1 | ABBVIE INC. | $1,350.00 | 12/10/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH ASSOCIATES | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | No dispute reported | 06/30/2026 | 1202529876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.88 | 12/01/2025 | Non-covered Recipient Entity Brookview Hills Research | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220699470 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $20,030.88 | 11/30/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220996680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 11/19/2025 | Non-covered Recipient Entity Brookview Hills Research | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220699472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 11/19/2025 | Non-covered Recipient Entity Brookview Hills Research | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220699474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 11/19/2025 | Non-covered Recipient Entity Brookview Hills Research | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220699476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25,015.00 | 11/17/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699466 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $80,123.52 | 10/31/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220996678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19,765.00 | 10/22/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699464 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 09/30/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220996676 |
| Principal investigator 1 | Amgen Inc. | $27,050.46 | 09/21/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH ASSOCIATES LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246639803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $26,315.00 | 09/08/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699462 |
| Principal investigator 1 | ABBVIE INC. | $14,964.00 | 09/04/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH ASSOCIATES | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | No dispute reported | 06/30/2026 | 1202509098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34,340.00 | 08/18/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699460 |
| Recipient | ABBVIE INC. | $15.00 | 08/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) | No dispute reported | 06/30/2026 | 1202398621 |
| Recipient | ABBVIE INC. | $52.88 | 08/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) | No dispute reported | 06/30/2026 | 1202398624 |
| Recipient | ABBVIE INC. | $15.00 | 08/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) | No dispute reported | 06/30/2026 | 1202398628 |
| Recipient | ABBVIE INC. | $234.78 | 08/07/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) | No dispute reported | 06/30/2026 | 1202398606 |
| Recipient | ABBVIE INC. | $215.46 | 08/07/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) | No dispute reported | 06/30/2026 | 1202398610 |
| Recipient | ABBVIE INC. | $15.00 | 08/07/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) | No dispute reported | 06/30/2026 | 1202398617 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 07/31/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220996674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29,215.00 | 07/07/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699458 |
| Principal investigator 1 | AstraZeneca UK Limited | $12,800.00 | 07/02/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH | Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) | No dispute reported | 06/30/2026 | 1185551631 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 06/30/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220996672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,920.00 | 06/09/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23,660.00 | 05/12/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,905.00 | 04/09/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,080.00 | 03/12/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,570.00 | 02/14/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220699448 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $80,123.52 | 01/31/2025 | Non-covered Recipient Entity Brookview Hills Research | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220996670 |
| Principal investigator 1 | Amgen Inc. | $330,276.54 | 01/27/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH ASSOCIATES LLC | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246639805 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $144,416.70 | 01/24/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185551625 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $600.00 | 01/24/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH | The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions | No dispute reported | 06/30/2026 | 1185551627 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,835.51 | 01/10/2025 | Non-covered Recipient Entity BROOKVIEW HILLS RESEARCH | TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal | No dispute reported | 06/30/2026 | 1185551623 |